GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Free Cash Flow

Radiopharm Theranostics (Radiopharm Theranostics) Free Cash Flow : $-16.35 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Free Cash Flow?

Radiopharm Theranostics's total free cash flow for the months ended in Dec. 2023 was $-7.88 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.35 Mil.

Radiopharm Theranostics's Free Cash Flow per Share for the months ended in Dec. 2023 was $-0.02. Its free cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.


Radiopharm Theranostics Free Cash Flow Historical Data

The historical data trend for Radiopharm Theranostics's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Free Cash Flow Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Free Cash Flow
-26.88 -16.60

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Free Cash Flow -23.32 -3.97 -8.17 -8.47 -7.88

Radiopharm Theranostics Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Radiopharm Theranostics's Free Cash Flow for the fiscal year that ended in Jun. 2023 is calculated as

Free Cash Flow (A: Jun. 2023 )=Cash Flow from Operations+Capital Expenditure
=-15.572+-1.028
=-16.60

Radiopharm Theranostics's Free Cash Flow for the quarter that ended in Dec. 2023 is calculated as

Free Cash Flow (Q: Dec. 2023 )=Cash Flow from Operations+Capital Expenditure
=-7.88+0
=-7.88

Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-16.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (OTCPK:RDPTF) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Jun23, Radiopharm Theranostics's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Jun23)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.09+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Radiopharm Theranostics Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022